Clinical trials: Metastases
Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
This pilot phase II trial studies how effective pembrolizumab and liver-directed therapy or peptide receptor radionuclide therapy are at treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or…
- Trial name
- NCT03457948
- Testing
- Arterial Embolization, Pembrolizumab, Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Nicholas Fidelman, MD
Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not…
- Trial name
- NCT04003610
- Testing
- Pemigatinib, Pembrolizumab, Gemcitabine
- Where
- 79 sites in United States, Austria and 14 more
- Volunteers
- 7 people
- Sponsor
- Incyte Corporation
Metastatic Solid Tumor
Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
The purpose of this research study is to determine the best dose of the combination of two approved drugs, intravenous topotecan and oral erlotinib.
- Trial name
- NCT00611468
- Testing
- Topotecan, Erlotinib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Accelerated Community Oncology Research Network
Fractures, Bone
A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
This is a randomized, double-blind, double-dummy study designed to provide bridging data in an Asian population to Amgen's studies of denosumab in subjects with bone metastases from solid tumors.
- Trial name
- NCT01920568
- Testing
- Denosumab 70 mg/mL, Zoledronic acid 4 mg, Calcium supplement
- Where
- 25 sites in China, Singapore and 1 more
- Volunteers
- 487 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
This study determines the proportion of metastatic breast cancer patients progression free after 6 months when treated with gemcitabine/ cisplatin/ trastuzumab or gemcitabine/ trastuzumab.
- Trial name
- NCT00201760
- Testing
- Gemcitabine, Trastuzumab, Cisplatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Kari Kendra
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Neoplasm, Advanced or Metastatic
A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants
The purpose of this study is to evaluate the relative bioavailability of a new tablet formulation of TAK-117 (new clinical trial material [NTM]) compared to the TAK-117 Process B capsules (current clinical trial material [CTM])…
- Trial name
- NCT02625259
- Testing
- TAK-117, Lansoprazole
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Liver Metastases From Colorectal Primary Cancer
Ultrasound Liver Intraoperative Imaging With SonoVue®
Hypothesis: Use of contrast ultrasound showed interesting results, which can increase ultrasonography sensitivity performed during surgery in the evaluation of operable liver metastases.
- Trial name
- ULIIS (NCT01880554)
- Testing
- Contrast-enhanced intraoperative ultrasound
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Institut Bergonié
Breast Neoplasm
Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer
The primary objective of this study is to determine whether overall response to cetuximab combined with cisplatin is better than overall response to cisplatin alone together with showing that the overall response for cetuximab…
- Trial name
- BALI-1 (NCT00463788)
- Testing
- cetuximab, cisplatin, cisplatin
- Where
- 46 sites in Australia, Austria and 9 more
- Volunteers
- 181 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Kawasaki Disease
Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities
Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the developed world. Despite available treatment, 25% of children in San Diego County appropriately treated for KD develop coronary artery…
- Trial name
- NCT01431105
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, San Diego
Non-small Cell Lung Cancer, NSCLC
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent…
- Trial name
- NCT04746924
- Testing
- Tislelizumab, Ociperlimab, Pembrolizumab
- Where
- 218 sites in United States, Argentina and 17 more
- Volunteers
- 669 people
- Sponsor
- BeiGene
Breast Cancer, Dermatologic Complications
Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ
RATIONALE: Steroid therapy, such as mometasone furoate, may prevent radiation dermatitis caused by radiation therapy. It is not yet known whether mometasone furoate is more effective than a placebo in preventing radiation…
- Conditions
- Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
- Trial name
- NCT00438659
- Testing
- mometasone furoate
- Where
- 189 sites in United States
- Volunteers
- 176 people
- Sponsor
- North Central Cancer Treatment Group
Esophageal Cancer
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with recurrent or metastatic…
- Trial name
- NCT00268346
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center
Hemorrhage
Reversal Dabigatran Anticoagulant Effect With Idarucizumab
The trial objective is to demonstrate the safety of idarucizumab, as assessed by the occurence of patients with drug related adverse events (including immune reactions) and all-cause mortality in paediatric venous thromboembolism…
- Trial name
- NCT02815670
- Testing
- Idarucizumab
- Where
- 2 sites in Russia
- Volunteers
- 1 people
- Sponsor
- Boehringer Ingelheim
Metastatic Breast Cancer With Intracranial Metastases
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
This phase II trial will combine two agents, cabazitaxel and lapatinib, to treat patients with metastatic breast cancer (MBC) which has metastasized to the brain.
- Trial name
- NCT01934894
- Testing
- cabazitaxel, lapatinib
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- SCRI Development Innovations, LLC
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease
The primary objective of the study was to evaluate the safety and tolerability of cinacalcet after a single oral dose in children aged 28 days to less than 6 years with chronic kidney disease receiving dialysis.
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Secondary Hyperparathyroidism
- Trial name
- NCT01290029
- Testing
- Cinacalcet
- Where
- 10 sites in United States, Germany and 1 more
- Volunteers
- 14 people
- Sponsor
- Amgen
Acute Myocardial Infarction, Coronary Artery Disease
Myocardial Infarction, COmbined-device, Recovery Enhancement Study
Unplanned readmissions after hospitalization for acute myocardial infarction (AMI) are among the leading causes of preventable morbidity, mortality, and healthcare costs.
- Conditions
- Acute Myocardial Infarction, Coronary Artery Disease, Acute Coronary Syndrome, Myocardial Infarction
- Trial name
- MiCORE (NCT03760796)
- Testing
- Corrie Health Digital Platform
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
This phase II trial studies how well regorafenib works together with methotrexate in treating participants with metastatic non-squamous non-small cell lung cancer with tumors that harbor a KRAS mutation.
- Conditions
- KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT03520842
- Testing
- Methotrexate, Pharmacokinetic Study, Regorafenib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Colorectal Cancer, Liver Neoplasms
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
This study is an open-label study. It has two stages. Stage 1 is a dose escalation phase of the study to determine and evaluate the safety and tolerability of repeated treatments with a genetically engineered herpes simplex virus…
- Trial name
- NCT00149396
- Testing
- NV1020
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- MediGene
Refractory Metastatic Colorectal Cancer
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
A Phase 2 Study with Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Participants with Microsatellite Stable Refractory Metastatic Colorectal Cancer
- Trial name
- NCT02860546
- Testing
- TAS-102, nivolumab
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Taiho Oncology, Inc.